Analyst picks & changes

Centocor Inc.

(CNTO)

Cor Therapeutics Inc.

(CORR)

Dillon Read's King upgraded CNTO to "outperform" from "neutral" following the release of disappointing data from CORR's Phase III trial of its Integrelin

GPIIb/IIIa

inhibitor in all comers

Read the full 367 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE